Prognostic value and computer image analysis of p53 in mantle cell lymphoma

[1] Jain P(2019)Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management Am J Hematol 94 710-725

[2] Wang M(2016)Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network Lancet (London, England) 388 565-575

[3] Hermine O(2012)Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10002 cases Journal of Diagnostics Concepts & Practice 11 111-115

[4] Hoster E(2008)A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Blood 111 558-565

[5] Walewski J(2016)Prognostic value of Ki-67 Index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34 1386-1394

[6] Bosly A(2020)p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma Br J Haematol 191 796-805

[7] Stilgenbauer S(2010)Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma Int J Oncol 36 699-706

[8] Thieblemont C(2021)Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma Sci Rep 11 11896-420

[9] Szymczyk M(2018)Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network Blood 131 417-108

[10] Bouabdallah R(2014)SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a Nordic Lymphoma Group study Br J Haematol 166 98-449

[1] Jain P(2019)Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management Am J Hematol 94 710-725

[2] Wang M(2016)Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network Lancet (London, England) 388 565-575

[3] Hermine O(2012)Distribution pattern of lymphoma subtypes in China: a nationwide multicenter study of 10002 cases Journal of Diagnostics Concepts & Practice 11 111-115

[4] Hoster E(2008)A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Blood 111 558-565

[5] Walewski J(2016)Prognostic value of Ki-67 Index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34 1386-1394

[6] Bosly A(2020)p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma Br J Haematol 191 796-805

[7] Stilgenbauer S(2010)Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma Int J Oncol 36 699-706

[8] Thieblemont C(2021)Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma Sci Rep 11 11896-420

[9] Szymczyk M(2018)Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network Blood 131 417-108

[10] Bouabdallah R(2014)SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma–a Nordic Lymphoma Group study Br J Haematol 166 98-449